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Introduction:
The BRCA1 breast cancer susceptibility gene was identified after a massive positional cloning effort focused on families containing at least four cases of breast cancer 1 . Once the gene was identified testing for mutations became clinically available. Subsequent analysis of women who carry a BRCA1 mutation has demonstrated that the penetrance (the likelihood one will develop cancer if you carry a mutation) is quite different depending on the population studied. Estimates of penetrance from the original Breast Cancer Linkage Consortium were as high as 80% for breast cancer. Other studies using unselected populations lead to estimates of 30-50%. Similarly, the risk for ovarian cancer is dependent on how the study is performed. One explanation for these different cancer risks is the potential for other genetic loci (termed modifier genes) to influence cancer risk.
There are several approaches to identify specific modifier loci in individuals who carry BRCA1 mutations. The most commonly used approach is to directly test loci that influence cancer risk in the general population or have a biologically plausible reason to hypothesize an influence on BRCA1. For example, specific alleles of a VNTR polymorphism in HRAS1 influences ovarian cancer risk in BRCA1 carriers. The latter approach is exemplified by studies of genes involved in the response to DNA damage. For example, a polymorphism in the 5' UTR (untranslated region) of the RAD51 gene influences cancer risk in women who carry BRCA2 mutations but not BRCA1 mutations. More recently, genome-wide studies for genetic modifiers have been initiated. The PI of this proposal is participating in a multi-institutional study through the Cancer Genetics Network to collect DNA samples and clinical data from hundreds of women who carry BRCA1 or BRCA2 mutations. Genome-wide scans will be used in a modified linkage approach to identify loci that influence the age of cancer diagnosis in these women. These linkage methods are likely to be successful but are very large-scale efforts that when successful still implicate a locus that may contain dozens to hundreds of genes. No straightforward methods are available to sort the genes in the region for potential to carry an important polymorphism. Therefore, in this Exploratory Award we proposed to develop an innovative approach to use the simple eukaryote, Saccharomyces cerevisiae, to rapidly screen the genome for mutations that modify genomic instability. The genes identified in this study can then be candidates for focused epidemiologic studies.
Though no direct ortholog of the human BRCA1 gene has been identified in the S. cerevisiae genome the human BRCA1 protein is similar to the budding yeast Rad9 protein in several ways 2 . rad9 mutant strains and BRCA1 mutant cells have defective G2 checkpoint responses and are sensitive to several forms of DNA damage including ionizing radiation, alkylating agent exposure and UV radiation. In addition, the ATM (mutated in ataxia telangiectasia) kinase phosphorylates BRCA1 in response to DNA damage just as Mec1, a S. cerevisiae ATM homolog, phosphorylates Rad9 in yeast. Furthermore, both BRCA1 and Rad9 proteins contain a C-terminal tandem repeat of the BRCT (Brca1 carboxy terminus) motif. Mutating the Rad9 BRCT domain results in phenotypes similar to those observed in rad9∆ strains confirming that it is an important functional domain. Mutations in the BRCA1 BRCT motif results in an increased risk of breast cancer in women.
As first reported by Weinert and Hartwell 3 , exponentially growing rad9∆ strains show a 10-to 20-fold increase in the spontaneous rate of chromosome loss. Recently, Klein and colleagues directly compared chromosome loss rates among a series of checkpoint defective S. cerevisiae strains. They found that rad9∆/∆ strains had a chromosome loss rate of 2.0x10 -5 compared with 2.0x10 -6 for a comparable wild type strain. Based on this conservation in function, we proposed to develop and perform novel genetic screens in yeast that will allow rapid identification of loci which when haploinsufficient modify the chromosome loss phenotype (either increase or decrease) of a rad9∆/∆ diploid strain. These genes will serve as candidate modifier loci of genomic instability resulting from loss of BRCA1function in mammary cells.
Body
In the sections below we document the progress towards completion of the tasks in the original statement of work. For each section we have included our progress towards completing that task. Figure 1 gives an overview of the strategy we developed over the course of this Exploratory Award to complete the genetic screen. Figure 1 Task 1b. We carried out a number of experiments to determine the expected level of CF loss rate in the parental strain and the variance in this measurement. After a number of trials we determined that if we streak out a strain on one eigth of a 10 cm petri dish we expect to see fewer then 1 sectored colony (out of about ~200 colonies in that area of the plate). We set this level for mutant strains to be further characterized in subsequent tasks as any mutant that had 4 or more sectors in the 1/8 streakout.
Task 1c. Dr. Hannah Klein has graciously supplied us with rad9∆/∆ yeast strains carrying a marked chromosome V for assaying mutation rates 4 . Chromosome V carries the CAN1 gene which encodes the yeast arginine permease, responsible for uptake of arginine and also capable of transporting the arginine ortholog and toxic drug Lcanavanine into the cell. Strains that are CAN1/can1-100 are sensitive to canavinine, but losing the wt copy of the gene confers resistance to the drug as it is no longer taken up into the cell. Loss of the wt copy can occurs through loss of the chromosome or recombination with the mutant allele, additively these compose the mutation rate of the cell.
The method used to measure chromosome loss rate is termed fluctuation analysis (FA). This allows one to determine actual mutation rate (as opposed to mutation frequency, which reflects both mutation/loss rates as well as the growth of the culture. Optimizing this task in order to efficiently screen the mutant strains derived in this strain took significant work (approximately 6 months). We utilized the Spectrofluor Plus purchased by this grant in order to rapidly quantify the growth rate of the mutant strains. . We have verified that this method allows us to calculate the chromosome loss rate of a given strain within a factor of 2 compared to prior published studies. In addition, the variance of measurements of the same strain done three times is also within a factor of two. Thus, this methodology is sufficient for our goal of identifying strains that have a chromosome loss rate that is about five-fold increased compared with the parental strain.
Task 2 -Perform insertional mutagenesis screen using Synder Library DNA into strains developed in Tasks 1 and 2. a. Assay for changes in chromosome loss rate. Progress: Task 2a: We optimized the method to use the LEU2 insertional Snyder library described in the original application. In order to screen the entire yeast genome we needed to screen approximately 30,000 LEU+ mutant colonies (giving 95% coverage of the genome) onto low adenine plates and counting the number of sectors. See Figure 3 for a breakdown of the sectoring phenotype of the 30,000 mutants.
Insertional mutants in the "consistently high sectorers" group were chosen for furthur study to include identification of the insertion site and quantification of the genome instability causing sectoring via fluctuation analysis.
Struck-out for sectoring phenotype 30,000 These 1225 were then restruck 3 additional times to test reproducibility of this phenotype. Classifications of the mutants were then created based on the sectoring phenotype seen in 4 separate streak-out trials. Two groups (boxes in yellow) were considered "consistently high sectorers" due to repetition of phenotype. 
Progress:
Task 3a: Vectorette PCR and Inverse PCR, utilizing 6 different restriction enzyme and multiple double digests for each, successfully identfied insertion site of 300 of the 398 insertional mutation in the reproducible population. Of these 300 sites identified, 171 insertions occurred in novel genes, 54 insertions occurred in "non-coding" regions between genes and the remaining 75 were repetitions of insertions in the aforementioned groups. Table 1 lists the unique insertion sites.
Task 3b: Fluctuation Analysis of 225 insertional mutants, that were classified in the "consistently high sectorers" category, has been completed. Confidence Interval calculations are currently being generated with the collaboration of Dr. Marek Kimmel and Xiaowei Wu at Rice University. Estimates from analysis of forty insertional mutants demonstrate that approximately 40% of the strains are statistically significantly different from the parental non-mutagenized strain, this compares with less then 10% (0 of 10 strains) that were randomly selected from the non-sectoring strains (figure 4).
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WT SECTORING MUTANTS RANDOM
3.50E- Ty1 enhancer activator  TELO8P  THI13  YDL244W  thiamin biosynthesis  THI21  YPL258C  thiamin biosynthesis  TIM11  YDR322C-A,ATP21  ATP synthesis  TMA17  YDL110C  unknown function  TOM1  YDR457W  regulates transcriptional coactivators  TPM2  YIL138C  binds to and stabilizes actin filaments  TPO5  YKL174C  polyamine transporter activity  TRP1  YDR007W  inv in amino acid metabolism  TRX1  YLR043C,LMA1  cytoplasmic thioredoxin isoenzyme  TSC11  YER093C,AVO3  inv in sphingolipid metabolism  TUB2 YFL037W,ARM10,SHE8 structural constituent of cytoskeleton UBP11 YKR098C ubiquitin-specific protease URM1 YIL008W ubiquitin-like protein 
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Progress:
Task 4a: Gene Ontology (GO) analysis was utilized to help create a list of genes to pursue further. By characterizing the percentage of genes from our screen versus the expected percentage found in the yeast genome GO annotations allow for identification of statistically significantly over-or under-represented groups. In our screen we found that genes involved in the cell cycle, meiosis or localized to the chromosome were significantly over-represented. We thus chose all of the genes from these groups as well as genes that would not have been found from prior studies including essential genes and hypothetical ORFs as our group of 67 genes-of-interest. Recreation of a clean heterozygous deletion of the gene (as opposed to an insertional mutant) was created in both rad9-/-and wt backgrounds for further analysis.
Fluctuation Analysis was performed twice on each of 134 (67 genes in two backgrounds) heterozygous mutants. The mutation rate was then compared to the insertional mutant strains to check for reproducibility of this phenotype. It was found that 89.5% of recreated clean knock-outs, in the rad9-/-background, have the same or greater mutation rate than the insertional mutation; 17.5% of this group have a greater impact on mutation rate in the clean background likley due to the complete deletion having a greated impact on the gene then an insertional mutant. Conversely, 10.5% of recreated clean knock-outs do not repeat the phenotype, possibly due to a second transposon insertion in the original mutant. Southern blots for transposon number are currently in this small number of strains.
Task 4b: Mutation rates in the wt and rad9-/-background were compared in order to determine Rad9 dependence of the increased genome instability. Surprisingly, the majority of mutants had an impact on both the wild type and rad9-/-mutant backgrounds. Only 7 of 67 mutant genes tested were rad9 dependent for demonstrating an increased mutation rate. Of the remaining 60 genes, 36 have a greater than 2 fold increase in mutation rate compared to their rad9-/-or wt parental counterpart. These appear to represent a group of genes that are able to impact genome instability in a heterozygous state. Semi-quantitative DNA damage assays utilizing exposure to MMS, HU, UV, Benomyl and Phleomycin were performed for this group of 67 mutant strains. The majority of heterozygous strains did not show increased sensitivity to these agents consistent with our prior assays focusing on spontaneous chromosome loss. A group of 21 mutant strains showed either increased sensitivity or resistance to one or more of these agents. These studies are being repeated to confirm these results.
Task 4c: Extensive homology and literature searches are underway to identify which of the 171 genes have human homologs or have homologous pathways in human cells. These genes with create a preliminary list of candidate modifier loci to be tested as part of ongoing genetic epidemiology studies. Professor Tim Rebbeck of the University of Pennsylvania has agreed to include polymorphisms from genes on this list in his ongoing epidemiology studies to identify second site genetic modifiers which impact the age of onset of cancer in women who carry BRCA1 or BRCA2 mutations. Writing of a scientific paper is underway and will be completed when analysis of the molecular mechanisms underlying the increased chromosome loss rate of a subset of genes is completed. An initial Final Report was submitted to the DOD on December 31, 2004. This additional Final Report was prepared as work on this project continued under a no cost extension during 2005. Given the importance of the project the PI has continued to complete this project using institutional funds and has submitted grant applications to the National Cancer Institute to continue this research.
Key Research Accomplishments
(1) Completion of the screening of 30,000 insertional mutatnts for effects on sectoring rate and identification of a group of with consistent genome instability. (2) Fluctuation Analysis generated mutation rates for all unique insertion sites identified as well as mutation rate calculations of 67 complete gene deletions in rad9-/-and wt backgrounds. (3) DNA damage assay results of all 67 heterozygous mutants in both rad9-/-and wt backgrounds.
Reportable Outcomes
Insertional mutagenesis coupled with efficient fluctuation analysis allows identification of heterozgyous mutations that impact the chromosome loss rate of a rad9∆/∆ mutant strain. 
Conclusions
The goal of this Exploratory Award was to investigate the novel hypothesis that we could develop a methodology to identify heterozygous mutants that impact the genomic stability of a rad9 mutant strain. We have completed this goal and have developed a protocol that allows efficient screening of the yeast genome for such mutations. Analysis of the mutant strains identified in this screen including analysis of the gene ontology of the isolated mutants and quantitative measurement of mutation rate demonstrate that the screen is able to identify heterozygous mutations that impact genomic stability in budding yeast. Analysis of the mutants obtained will allow us to identify a set of genes which are candidates for modifiers of BRCA1 function. Professor Timothy Rebbeck of the University of Pennyslvania has expressed interest in using these loci in his ongoing epidemiology study to identify genetic modifiers that impact that age of onset of breast cancer in women who carry mutations in BRCA1.
